

David Burger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1090881/david-burger-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

207 papers	3,391 citations	30 h-index	47 g-index
222 ext. papers	4,147 ext. citations	5.4 avg, IF	5.49 L-index

#	Paper	IF	Citations
207	Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.. <i>Pediatric Infectious Disease Journal</i> , 2022 , 41, 131-132	3.4	0
206	Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?. <i>Aids</i> , 2022 , 36, 322-323	3.5	0
205	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022 , 36, 75-82	3.5	2
204	Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.. <i>Lancet HIV</i> , 2022 ,	7.8	2
203	An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.. <i>Clinical Pharmacokinetics</i> , 2022 , 1	6.2	1
202	Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.. <i>Clinical Pharmacokinetics</i> , 2022 , 61, 619	6.2	0
201	The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021 , 72, 121-127	11.6	7
200	First pharmacokinetic data of bictegravir in pregnant women living with HIV. <i>Aids</i> , 2021 , 35, 2405-2406	3.5	1
199	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021 , 21, 9-27	3.4	15
198	Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106293	14.3	0
197	COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 212-213	3.8	15
196	Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1256-1258	11.6	34
195	The bioavailability and maturing clearance of doxapram in preterm infants. <i>Pediatric Research</i> , 2021 , 89, 1268-1277	3.2	2
194	Association between healthcare practitioners' beliefs about statins and patients' beliefs and adherence. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1082-1088	3.8	2
193	Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 288-293	2.9	1
192	A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 161-172	4.5	1
191	Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 649-654	6.2	3

190	The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1273-1276	5.1	3
189	More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine. <i>International Journal of Infectious Diseases</i> , 2021 , 103, 402-403	10.5	0
188	The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3359-3363	3.8	3
187	High unbound flucloxacillin fraction in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3220-3228	5.1	3
186	Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, 1072-1078	3.1	0
185	The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. <i>International Journal of Cancer</i> , 2021 , 148, 2799-2806	7.5	1
184	A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy. <i>Clinical Biochemistry</i> , 2020 , 83, 86-88	3.5	
183	Cumulative pemetrexed dose increases the risk of nephrotoxicity. <i>Lung Cancer</i> , 2020 , 146, 30-35	5.9	10
182	Pharmacokinetics and Generic Drug Switching: A Regulator's View. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1065-1069	6.2	3
181	Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DOLPHIN-2): an open-label, randomised controlled trial. <i>Lancet HIV</i> , 2020 , 7, e332-e339	7.8	30
180	Cobicistat: A case of mislabelled drug-drug interaction risk?. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 834-836	3.8	3
179	Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25501	5.4	5
178	Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands. <i>Clinical and Translational Science</i> , 2020 , 13, 599-607	4.9	2
177	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 753-760	3.5	3
176	Implications for IV posaconazole dosing in the era of obesity. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1006-1013	5.1	10
175	Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105934	14.3	4
174	Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of Antiretroviral agents in HIV-infected pregnant women (PANNA) Network. <i>Clinical Infectious Diseases</i> , 2020 , 71, e714-e717	11.6	4
173	Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 770-774	6.1	4

172	SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. <i>Antiviral Therapy</i> , 2020 , 25, 345-347	1.6	7
171	Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2213-2215	11.6	9
170	Effectiveness of medication review on the number of drug-related problems in patients visiting the outpatient cardiology clinic: A randomized controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 50-61	3.8	4
169	Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1352-1361	6.1	15
168	A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 231-235	3.5	1
167	Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 231-243	6.1	23
166	Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 45-57	5.5	6
165	Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS. <i>Biomedical Chromatography</i> , 2020 , 34, e4758	1.7	13
164	Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 146-150	3.2	1
163	Pharmacokinetics of tenofovir disoproxil fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy. <i>Aids</i> , 2020 , 34, 1989-1991	3.5	3
162	Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2661-2665	5.1	3
161	Drug switching in the Netherlands: a cohort study of 20 active substances. <i>BMC Health Services Research</i> , 2020 , 20, 650	2.9	6
160	Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. <i>Lancet HIV</i> , 2020 , 7, e533-e544	7.8	11
159	Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3417-3424	5.1	16
158	Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 223, 941-943	6.4	1
157	Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	11
156	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3433-3457	5.1	9
155	Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 738-750	6.1	25

- 154 A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. *Cancer Chemotherapy and Pharmacology*, **2019**, 84, 1179-1185^{3.5} 4
- 153 The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study). *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1076-1082 6.1 12
- 152 Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution - AuthorsTreply. *Lancet Oncology, The*, **2019**, 20, e290 21.7
- 151 Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. *Clinical Pharmacokinetics*, **2019**, 58, 1237-1263 6.2 34
- 150 Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. *Lancet Oncology, The*, **2019**, 20, e200-e207 21.7 34
- 149 Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus. *Clinical Infectious Diseases*, **2019**, 69, 1254-1258 11.6 27
- 148 Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1348-1356^{5.1} 5
- 147 Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. *Lung Cancer*, **2019**, 130, 156-158 5.9 7
- 146 Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. *Clinical Pharmacokinetics*, **2019**, 58, 309-323 6.2 26
- 145 Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1093-1098^{6.1} 3
- 144 Generic substitution of antiretroviral agents: never a problem?. *Antiviral Therapy*, **2019**, 24, 389-391 1.6
- 143 Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 3537-3545 5.1 6
- 142 A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. *Journal of Clinical Oncology*, **2019**, 37, 4564-4564 2.2 2
- 141 Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review. *Antiviral Therapy*, **2019**, 24, 529-540 1.6 4
- 140 Does a food intervention makes abiraterone treatment affordable?. *Journal of Clinical Oncology*, **2019**, 37, e16523-e16523 2.2
- 139 Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2019**, 1110-1111, 15-24 3.2 23
- 138 Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. *Therapeutic Drug Monitoring*, **2019**, 41, 431-443 3.2 7
- 137 Carbamazepine intervention in a patient with efavirenz-induced liver injury. *Aids*, **2019**, 33, 1097-1098 3.5 1

136	Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 730-737	6.1	6
135	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 986-990	5.1	8
134	Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. <i>Journal of Hepatology</i> , 2019 , 70, 552-554	13.4	9
133	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 978-985	5.1	8
132	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. <i>Pediatric Nephrology</i> , 2019 , 34, 507-515	3.2	7
131	Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1185, 71-81	3.2	22
130	Cardiovascular Risk Management and Hepatitis C: Combining Drugs. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 565-592	6.2	12
129	The Combination of Enzalutamide and Opioids: A Painful Pitfall?. <i>European Urology</i> , 2019 , 75, 351-352	10.2	4
128	Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy. <i>HIV Medicine</i> , 2019 , 20, 63-68	2.7	10
127	Efavirenz pharmacokinetics during pregnancy and infant washout. <i>Antiviral Therapy</i> , 2019 , 24, 95-103	1.6	10
126	Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. <i>Antiviral Therapy</i> , 2018 , 23, 259-265	1.6	1
125	Safe use of proton pump inhibitors in patients with cirrhosis. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1806-1820	3.8	21
124	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. <i>Targeted Oncology</i> , 2018 , 13, 363-370	5	3
123	Large differences in neonatal drug use between NICUs are common practice: time for consensus?. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1313-1323	3.8	23
122	A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1575-1586	3.8	8
121	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 222-229	3.2	8
120	Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics. <i>Tropical Medicine and International Health</i> , 2018 , 23, 295-305	2.3	4
119	Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 966-973	6.1	3

118	Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. <i>Drug Safety</i> , 2018 , 41, 603-613	5.1	24
117	Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	14
116	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400mg in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1421-1433	6.2	5
115	The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. <i>Annual Review of Pharmacology and Toxicology</i> , 2018 , 58, 271-291	17.9	28
114	Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 477-481	3.8	4
113	Parenteral bilirubin in healthy volunteers: a reintroduction in translational research. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 268-279	3.8	9
112	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 122-129	3.8	25
111	Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 1585-1591	2.8	9
110	Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1089, 16-23	3.2	5
109	Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3095-3101	5.1	7
108	Development of an online drug-drug interaction resource to support safe prescription of oncolytics.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18574-e18574	2.2	
107	Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect. <i>HIV Medicine</i> , 2018 , 19, 216-226	2.7	11
106	Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 705-716	6.2	35
105	Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 267-286	6.2	36
104	Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 1008-1010	3.4	1
103	The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report. <i>Annals of Hepatology</i> , 2018 , 17, 525-529	3.1	2
102	First reported use of zidovudine for prevention of perinatal HIV transmission in a premature neonate on extra corporal membrane oxygenation. <i>Aids</i> , 2018 , 32, 2084-2085	3.5	
101	Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2430-2434	5.1	8

100	Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1287-1297	3.8	7
99	Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring. <i>European Neuropsychopharmacology</i> , 2017 , 27, 205-216	1.2	19
98	Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 379-382	14.3	19
97	A call for a consortium for optimal management of drug-drug interactions in patient care. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 391-394	6.1	3
96	Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2225-2234	3.8	6
95	Poorly specified fasting conditions in clinical research could lead to treatment failure. <i>Lancet Oncology, The</i> , 2017 , 18, 571-573	21.7	1
94	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2195-2204	3.8	40
93	Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1335-1341	11.6	40
92	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017 , 31, e3986	1.7	15
91	Zidovudine continuous infusion in an HIV-infected pregnant woman with a phobia of swallowing pills. <i>Antiviral Therapy</i> , 2017 , 22, 727-729	1.6	
90	Effectiveness of medication review: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Family Practice</i> , 2017 , 18, 5	2.6	95
89	Fasting conditions in clinical oncology trials and drug labelling - AuthorsTreply. <i>Lancet Oncology, The</i> , 2017 , 18, e507	21.7	
88	Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. <i>PLoS ONE</i> , 2017 , 12, e0173509	3.7	21
87	The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions. <i>United European Gastroenterology Journal</i> , 2017 , 5, 648-657	5.3	21
86	Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 864-872	6.1	1
85	Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2312-2314	3.8	4
84	In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2789-2797	3.8	8
83	Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 109S, S90-S97	5.1	21

82	Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. <i>International Journal of Infectious Diseases</i> , 2017 , 61, 89-96	10.5	8
81	Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 490-495	5.1	4
80	Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 486-489	5.1	3
79	CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 235-246	2.9	20
78	Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 190-199	5.1	9
77	Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9540-9540	2.2	
76	Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. <i>AIDS Reviews</i> , 2017 , 19, 16-23	1.5	7
75	Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 347-8	14.3	9
74	A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 667-78	3.8	14
73	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. <i>European Respiratory Journal</i> , 2016 , 48, 932-4	13.6	6
72	Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1471-1494	6.2	23
71	Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2016 , 16, 169-79	25.5	25
70	Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3372-9	5.9	58
69	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 723-33	6.2	27
68	Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. <i>Tuberculosis</i> , 2016 , 96, 150-7	2.6	31
67	Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 480-3	5.1	24
66	Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 381-96	6.2	35
65	Food intervention to make therapy with pazopanib more patient-friendly and affordable.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11040-11040	2.2	2

64	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 330-330	2.2	1
63	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 329-329	2.2	
62	Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. <i>Pediatric Transplantation</i> , 2016 , 20, 492-9	1.8	8
61	Improved labelling of antiretrovirals for paediatric use. <i>Lancet HIV,the</i> , 2016 , 3, e550-e551	7.8	1
60	A new paediatric formulation of valaciclovir: development and bioequivalence assessment. <i>Archives of Disease in Childhood</i> , 2016 , 101, 971-2	2.2	2
59	Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. <i>BMJ Open</i> , 2016 , 6, e012991	3	19
58	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1447-1456	6.2	11
57	Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, e76-e81	25.5	14
56	Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 622-630	2.4	3
55	Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. <i>Drug Safety</i> , 2016 , 39, 589-611	5.1	56
54	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1369-1380	6.2	54
53	The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 725-30	2.8	7
52	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 185-98	3.8	22
51	Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. <i>Current Opinion in Pharmacology</i> , 2015 , 24, 38-44	5.1	47
50	Dose optimization of raltegravir chewable tablets in a 4-year-old HIV-infected child. <i>Clinical Infectious Diseases</i> , 2015 , 61, 294-5	11.6	1
49	Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3233-9	5.9	17
48	Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 496-503	14.3	59
47	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4403-9	5.9	40

46	Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. <i>Clinical Infectious Diseases</i> , 2015 , 61, 809-16	11.6	46
45	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3240-5	5.9	32
44	Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 534-42	5.1	29
43	A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1166-74	5.1	18
42	Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1933-7	5.1	2
41	Effectiveness of Drug Interventions Reducing Nevirapine Resistance after Single-dose Exposure for Perinatal HIV Prevention. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A165-A166	1.6	
40	Pharmacokinetics of caspofungin in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3294-9	5.1	52
39	Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1475-82	1.2	34
38	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2988-94	5.1	23
37	Managing drug-drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: a Tour de force for clinical pharmacologists. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 86-8	14.3	2
36	Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 409-27	6.2	30
35	Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 173-7	14.3	13
34	Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 229-34	14.3	51
33	Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis. <i>Journal of Clinical Virology</i> , 2014 , 60, 431-2	14.5	6
32	Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 824-7	3.2	4
31	The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19789	5.4	1
30	Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 410-25	27.4	384
29	Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6879-85	5.9	55

28	Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warning. <i>Topics in Antiviral Medicine</i> , 2014 , 21, 165-8	3.2	9
27	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. <i>Annals of Hepatology</i> , 2014 , 13, 452-5	3.1	8
26	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , 2013 , 58, 792-800	13.4	88
25	Population pharmacokinetics of abacavir in infants, toddlers and children. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1525-35	3.8	8
24	Drug-drug interactions in HIV therapy: is it all clear?. <i>Antiviral Therapy</i> , 2013 , 18, 649-650	1.6	3
23	Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer. <i>Annals of Oncology</i> , 2012 , 23, 801-802	10.3	6
22	The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 458-63	9.4	87
21	Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 369-72	3.2	11
20	The role of therapeutic drug monitoring in pediatric HIV/AIDS. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 269-72	3.2	5
19	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-. <i>Antiviral Therapy</i> , 2010 , 15, 297-305	1.6	22
18	The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. <i>Antiviral Therapy</i> , 2009 , 14, 443-450	1.6	16
17	Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. <i>Antiviral Therapy</i> , 2009 , 14, 241-248	1.6	18
16	The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 698-703	6.1	37
15	Drug interactions between statins and antiretroviral agents. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 247-51	4.2	5
14	Determination of Emtricitabine in Human Plasma using HPLC with Fluorometric Detection. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2007 , 30, 2769-2778	1.3	17
13	Age-dependent pharmacokinetics of lamivudine in HIV-infected children. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 517-20	6.1	26
12	Reverse transcriptase inhibitors in HIV/AIDS therapy. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 634-634	3.8	1
11	Nevirapine Concentrations in HIV-Infected Children treated with Divided Fixed-Dose Combination Antiretroviral Tablets in Malawi and Zambia. <i>Antiviral Therapy</i> , 2007 , 12, 253-260	1.6	34

10	Nevirapine-Based Antiretroviral Therapy Started Early in the Course of Tuberculosis Treatment in Adult Malawians. <i>Antiviral Therapy</i> , 2007 , 12, 515-521	1.6	18
9	Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 1127-1132	1.6	45
8	Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen. <i>Antiviral Therapy</i> , 2007 , 12, 1265-1272 ^{1.6}		5
7	Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3336-42	5.9	55
6	Pharmacokinetics of a Once-Daily Regimen of Lopinavir/Ritonavir in HIV-1-Infected Children. <i>Antiviral Therapy</i> , 2006 , 11, 439-445	1.6	12
5	Pharmacokinetics of Reduced-Dose Indinavir/Ritonavir 400/100 Mg Twice Daily in HIV-1-Infected Thai Patients. <i>Antiviral Therapy</i> , 2005 , 10, 301-307	1.6	23
4	Nevirapine Plasma Concentrations and Concomitant Use of Rifampin in Patients Coinfected with HIV-1 and Tuberculosis. <i>Antiviral Therapy</i> , 2005 , 10, 937-943	1.6	25
3	Role of the Inhibitory Quotient in HIV Therapy. <i>Antiviral Therapy</i> , 2005 , 10, 879-892	1.6	22
2	Safety and Efficacy of a Nrti-Sparing Haart Regimen of Efavirenz and Lopinavir/Ritonavir in HIV-1-Infected Children. <i>Antiviral Therapy</i> , 2004 , 9, 297-299	1.6	6
1	COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.		3